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Abstract
Background: No comparisons have been made of scales estimating cardiovascular mortality and
overall cardiovascular morbidity and mortality. The study objectives were to assess the agreement
between the Framingham-D'Agostino cardiovascular risk (CVR) scale and the chart currently
recommended in Europe (SCORE) with regard to identification of patients with high CVR, and to
describe the discrepancies between them and the attendant implications for the treatment of
hypertension and hyperlipidaemia.
Methods: A total of 474 hypertensive patients aged 40–65 years monitored in primary care were
enrolled into the study. CVR was assessed using the Framingham-D'Agostino scale, which estimates
the overall cardiovascular morbidity and mortality risk, and the SCORE chart, which estimates the
cardiovascular mortality risk. Cardiovascular risk was considered to be high for values ≥ 20% and
≥ 5% according to the Framingham-D'Agostino and SCORE charts respectively. Kappa statistics
was estimated for agreement in classification of patients with high CVR. The therapeutic
recommendations in the 2007 European Guidelines on Cardiovascular Disease Prevention were
followed.
Results: Mean patient age was 54.1 (SD 7.3), and 58.4% were males. A high CVR was found in
17.5% using the SCORE chart (25.3% males, 6.6% females) and in 32.7% using the D'Agostino
method (56.9% males, 12,7% females). Kappa coefficient was 0.52, and increased to 0.68 when the
high CVR threshold was established at 29% according to D'Agostino. Hypertensive patients with
high SCORE and non-high D'Agostino (1.7%) were characterized by an older age, diabetes, and a
lower atherogenic index, while the opposite situation (16.9%) was associated to males,
hyperlipidaemia, and a higher atherogenic index. Variables with a greater weight in discrepancies
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were sex and smoking. A 32.0% according to SCORE and 33.5% according to D'Agostino would be
candidates to receive antihypertensive treatment, and 15.8% and 27.3% respectively to receive
lipid-lowering treatment.
Conclusion: A moderate to high agreement was found. SCORE may underestimate risk in males
with an unfavourable lipid profile, and D'Agostino in diabetics with a lower atherogenic risk. Use
of the D'Agostino scale implies treating more patients with lipid-lowering and antihypertensive
drugs as compared to SCORE.
Background
Arterial hypertension (AH) is the most prevalent cardio-
vascular risk (CVR) factor and the leading cause of mor-
bidity and mortality from cardiovascular disease in Spain.
AH is related to 46.4% of deaths from cerebrovascular dis-
ease and to 42% of deaths from heart disease[1,2].
Current clinical guidelines recommend estimation of car-
diovascular risk in patients with hypertension and dyslip-
idaemia to graduate treatment intensity and thus optimise
cost-effectiveness [3-5].
Both the European Guidelines on Cardiovascular Disease
Prevention and the Interdisciplinary Spanish Committee
for Cardiovascular Prevention (CEIPC)[6] recommend
use of the SCORE (Systematic Coronary Risk Evaluation)
charts[7], which estimate the risk of death from cardiovas-
cular disease, although their calibration in Spain has
shown that they underestimate the risk of cardiovascular
morbidity and mortality[8]. A new scale based on the
Framingham Heart Study (D'Agostino)[9] intended to
estimate the risk of morbidity and mortality from cardio-
vascular disease has recently been published.
A review of the multiple studies published in recent years
reveals that there is no ideal scale for assessing CVR in
Mediterranean populations. The original Framingham
function[10,11] in its different versions, identifies more
patients with a high CVR than the SCORE chart[12,13].
However, its calibration for the Spanish population
(REGICOR)[14,15] identifies less patients with a high
CVR than the original scale[16,17], and agreement in
identification of patients with high CVR is low [18-21]. It
should be kept in mind that scales derived from the Fram-
ingham function estimate the incidence of coronary artery
disease, except for the D'Agostino scale, which estimates
overall cardiovascular morbidity and mortality, whereas
SCORE estimates cardiovascular mortality. The Framing-
ham scales are commonly used as a standard to assess
other methods, such as the presence of calcium in the cor-
onary artery[22], and also for assessing the effectiveness of
certain interventions[23]. However, no analysis has been
made of agreement between the SCORE and D'Agostino
scales and of the patient subgroups in which they disa-
gree. The attendant therapeutic implications in patients
with hypertension and hypercholesterolaemia have not
been studied either.
Therefore, the aims of this study were to assess the agree-
ment between these scales in hypertensive patients aged
40–65 years, to describe patient characteristics that are
associated to disagreement in identification of patients
with a high CVR, and to assess the impact of both func-
tions on therapeutic indications for blood pressure and
hypercholesterolaemia.
Methods
Study population
Patients with a clinical diagnosis of arterial hypertension
from to urban health care centres covering a population of
46.000 inhabitants. For this analysis, 474 patients with
clinical hypertension referred to the research unit for con-
firmation of diagnosis by ambulatory blood pressure
monitoring (ABPM) or evaluation of target organ lesions
in cases with documented hypertension were consecu-
tively enrolled from December 2005 to June 2008.
Patients had to meet the following inclusion criteria: (a)
age ranging from 40 and 65 years, and (b) no history of
established cardiovascular disease. Variables analysed
included all those required to estimate CVR using both
scales.
Measurements of risk factors and cardiovascular risk
Risk factors for morbidity and mortality used by the
D'Agostino scale [9] include age, sex, total cholesterol,
high-density lipoprotein cholesterol (HDL-C), and systo-
lic blood pressure (SBP) as quantitative variables, and
drug treatment for AH, smoking, and history of diabetes
mellitus as dichotomous variables. Risk of cardiovascular
morbidity and mortality was estimated using the pub-
lished risk equation based on the Framingham study[9].
Cardiovascular death risk variables used by SCORE
include age, sex, total cholesterol, SBP, and smoking as
dichotomous variable. These tables do not include diabe-
tes as a CVR factor, but authors recommend multiplica-
tion by 4 in females and by 2 in males if diabetes is found,
and this was the option adopted in our study. To estimate
cardiovascular risk with SCORE, the version for low risk
countries, using total cholesterol from the risk equationBMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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based on European cohorts, has been used[7]. The follow-
ing variables were also collected: blood glucose, full lipid
profile, body mass index (BMI), and use of lipid lowering
drugs.
Measurements were performed by nursing staff at the
research unit. Blood pressure was measured using
OMROM M7® sphygmomanometers in accordance with
the recommendations by the European Society of Hyper-
tension[24]. Lipid and blood glucose levels were meas-
ured blindly at the reference laboratory after fasting for at
least 8 hours. Data on CVR factors were taken from the
clinical history of each patient. The study was approved by
independent ethics committee from University Hospital
of Salamanca (Spain), and all participants signed an
informed consent.
Patient classification according to risk
Patients with a risk of cardiovascular morbidity and mor-
tality ≥ 20% in the Framingham-D'Agostino scales and a
risk of cardiovascular death ≥ 5% in the SCORE charts
were considered to have a high CVR. A CVR ranging from
6%–20% according to D'Agostino and from 3%–4.9%
according to SCORE was considered as moderate, and a
risk < 6% in the D'Agostino scale and < 3% in the SCORE
scale was considered as low, in agreement to recommen-
dations published by the authors[7,9].
The recommendations in the 2007 European Guidelines
on Cardiovascular Disease Prevention were applied to
estimate the proportion of patients amenable to drug
treatment (antihypertensive or lipid lowering). Candi-
dates to receive antihypertensive drug treatment include
patients with SBP ≥ 160 mmHg or DBP ≥ 100 mmHg, irre-
spective of their CVR, patients with SBP ≥ 140 mmHg or
DBP ≥ 90 mmHg and a CVR ≥ 5% according to SCORE or
≥ 20% according to D'Agostino or diabetics, and patients
with SBP ranging from 140–159 mmHg or DBP ranging
from 90–99 mmHg and a moderate CVR according to
SCORE or D'Agostino. With regard to plasma lipid con-
trol, patients with total cholesterol > 320 mg/dL and LDL-
C > 240 mg/dL, diabetes or a CVR ≥ 5% according to
SCORE or ≥ 20% according to D'Agostino, and total cho-
lesterol ≥ 190 mg/dL and/or LDL-C ≥ 115 mg/dL are con-
sidered to be candidates to drug treatment. To perform
calculations, antihypertensive or lipid lowering treat-
ments were considered to be adequately indicated in sub-
jects who were already receiving them[12,13,25].
Statistical analysis
Characteristics of patients studied and the CVR levels were
described using measures of central tendency and disper-
sion for quantitative variables and percentages for categor-
ical variables. These measures were compared between
different subgroups using a Student's t test for quantitative
variables and qualitative variables of two categories, and a
Chi-square test for qualitative variables. kappa coefficient
was used to assess agreement of both scales in study sub-
jects. Agreement was considered "excellent" when values
ranging from 0.81–1 were obtained, "good" when values
ranged from 0.61–0.80, and "moderate" when values of
0.41–0.60 were found[26], and a Pearson's correlation
was applied for quantitative measurement. In order to
assess the association between patient characteristics and
disagreement in categorisation as high risk for both scales,
a multivariate analysis was performed using the forward
stepwise logistic regression method, taking as dependent
variable the discrepancies between the two equations, and
including age, sex, smoking, present or absent diabetes,
basal blood glucose, total cholesterol, HDL-C, athero-
genic index, SBP, and DBP as independent variables. To
assess the diagnostic accuracy of SCORE as compared to
the different cut-off points of high CVR in the D'Agostino
scale, the area under the ROC curve was used. A value of p
≤ 0.05 was considered statistically significant. All analyses
were performed using SPSS/PC+ version 15.0 software.
Results
Study population
Among the total 914 hypertensive patients seen at the
research unit during the study period, 474 (52%) were
within the recommended age range for use of scales and
had no history of cardiovascular disease. Table 1 shows
blood pressure values and levels of different biochemical
markers, as well as sex differences in patients participating
in the study.
Estimated cardiovascular risk
Mean CVR was 18% (95% CI 16.78–19.21) according to
D'Agostino and 2.97% (95% CI 2.61–3.33) according to
SCORE, with a Pearson's correlation coefficient of 0.836
(p = 0.000) between both scales.
The proportions of patients considered to have a high
CVR were 17.5% with SCORE (25.3% in males and 6.6%
in females) and 32.7% with D'Agostino (46.9% in males
and 12.7% in females) (p < 0.05). Figure 1 shows the pro-
portions of patients included in the low, moderate, and
high CVR categories, both overall and by sex.
Table 2 shows distribution of the population based on the
presence of a high or non-high CVR, using high risk cut-
off points of 20% for the D'Agostino scale and 5% for
SCORE. Disagreement was found in 18.57% of patients
(high CVR in one chart and non-high CVR in the other
chart). Of these, 16.88% had a high CVR according to
D'Agostino and a non-high CVR with SCORE, while the
opposite occurred in the remaining 1.69%. However,
when the 163 patients rated as having a high CVR by anyBMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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scale were only analysed, the disagreement rate increased
to 54% of cases.
Figure 2 shows the percentages of subjects with high CVR
according to D'Agostino for different cut-off points, with
their kappa indexes as compared to SCORE. The kappa
index was higher as the high CVR cut-off point in the
D'Agostino scale increased, with the greatest agreement
being found in the cut-off point of 29% (kappa 0.678
[95% CI, 0.632–0.724]), in which 90.93% of patients
were classified in the same way using both scales.
Figure 3 shows the discriminating power, calculated using
the ROC curve between 5% in SCORE and different cut-
off points for high CVR according to D'Agostino. The area
under the curve was 0.915. The optimum cut-off point in
the D'Agostino scale was 25% (sensitivity 88% and specif-
icity 86%). At this threshold, disagreement in classifica-
tion of patients with high CVR with the D'Agostino scale
as compared to SCORE was only 11.6%.
Analysis of discordant patients
Most disagreeing patients, i.e., hypertensive patients rated
as high CVR in a scale and not high CRV in the other, cor-
respond to the group with a high CVR in the D'Agostino
scale and not high in the SCORE scale. This group show a
greater proportion of males (80% versus 50%), higher
mean LDL-C levels (141 versus 107 mg/dL), and a higher
proportion of patients treated with antihypertensive drugs
(77% versus 37%). Only eight hypertensive patients were
rated as high CVR with the SCORE scale and not high with
the D'Agostino scale (Table 3).
Table 4 shows the variables independently associated to
discrepancies. Variables with greater odds ratios included
sex (being male) (2.45) and smoking (1,86).
Therapeutic implications
Compliance with the recommendations in the European
Guidelines on Cardiovascular Disease Prevention would
imply that 32% of patients without treatment, according
to the SCORE function, and 33.5% of patients according
to the D'Agostino chart would be candidates to receive
antihypertensive drugs, and 15.8% and 27.3% of patients
without treatment respectively would be candidates to
receive lipid lowering drugs. Lipid lowering and antihy-
pertensive drugs would be indicated in a significantly
higher percentage of males as compared to females (Table
5).
Discussion
In this study on hypertensive patients aged 40–65 years
with no history of cardiovascular disease, agreement in
identification of patients with high CVR between the
SCORE equation[7] for low-risk countries using a cut-off
point of 5% and the D'Agostino equation[9] using a cut-
off point of 20% was moderate (kappa = 0.52), and
increased when the cut-off point in this second scale was
increased to 29% (kappa = 0.68).
Table 1: Characteristics of study patients, overall and by sex.
Overall (n=74) Males (n = 277) Females (n = 197) p
Age (years) 54.10 ± 7.27 54.09 ± 7.49 54.12 ± 6.97 0.962
Obese (BMI > 30) 153 (32.3%) 92 (33.2%) 61 (31.0%) 0.606
Smokers 111 (23.4%) 69 (24.9%) 42 (21.3%) 0.363
Diabetics 73 (15.4%) 52 (18.8%) 21 (10.7%) 0.016
Hyperlipidaemic 314 (66.2%) 174 (62.8%) 140 (71.1%) 0.038
BMI 28.72 ± 4.71 28.91 ± 4.14 28.46 ± 5.41 0.310
Waist circumference 96.04 ± 12.38 100.10 ± 9.99 90.28 ± 13.15 0.000
Glucose (mg/dL) 100.28 ± 28.04 103.32 ± 30.76 95.94 ± 23.00 0.006
Cholesterol/HDL ratio 4.12 ± 1.09 4.38 ± 1.12 3.76 ± 0.94 0.000
Total cholesterol (mg/dL) 214.70 ± 35.92 211.70 ± 36.17 218.92 ± 35.22 0.031
HDL-C (mg/dL) 54.85 ± 14.44 50.54 ± 12.34 60.92 ± 15.01 0.000
LDL-C (mg/dL) 134.18 ± 32.99 134.37 ± 32.46 133.92 ± 33.83 0.888
Triglycerides (mg/dL) 115.26 ± 73.81 137.79 ± 80.32 128.38 ± 61.47 0.001
Systolic blood pressure (mmHg) 140.99 ± 18.92 142.86 ± 16.49 138.37 ± 21.65 0.011
Diastolic blood pressure (mmHg) 89.09 ± 10.40 89.70 ± 9.67 88.24 ± 11.32 0.132
Antihypertensive drugs 271 (57.2%) 159 (57.4%) 112 (56.9%) 0.905
Lipid lowering drugs 75 (15.8%) 52 (18.8%) 23 (11.7%) 0.037
CVR by SCORE* 2.97 ± 4 3.94 ± 4.66 1.61 ± 2.18 0.000
CVR by D'Agostino** 18.00 ± 13.45 22.88 ± 14.66 11.12 ± 7.22 0.000
Hyperlipidaemic: cholesterol > 200 mg/dl. BMI: body mass index; HDL: high-density lipoprotein; HDL-C: high density lipoprotein cholesterol; LDL-
C: low density lipoprotein cholesterol. CVR: cardiovascular risk. Significant differences between males and females. P value: Differences between 
males and females. Data are shown as mean ± standard deviation or as number and percentages. *Cardiovascular mortality risk as percent risk and 
estimated at 10 years. **Cardiovascular morbidity and mortality risk as percent risk and estimated at 10 years.BMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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The population with high CVR according to SCORE and a
non-high CVR according to D'Agostino consisted of older
patients with diabetes and a lower atherogenic index,
while a greater proportion of males with a higher athero-
genic index and on antihypertensive treatment were
found in the group with high CVR using the SCORE equa-
tion and non-high CVR using the D'Agostino equation.
SCORE may underestimate CVR in males with an unfa-
vourable lipid profile and treated with drugs for AH as
compared to the D'Agostino method. By contrast, the
D'Agostino equation may underestimate CVR in elderly
patients with diabetes and higher HDL-C levels as com-
pared to the SCORE chart.
As regards therapeutic decisions, use of the D'Agostino
classification of CVR implies treating 3.5% more males
with antihypertensive drugs and 11.6% more patients
with lipid lowering drugs (mainly at the expense of males)
as compared to when the SCORE equation is used. Thus,
if SCORE is used, we will leave untreated a significant
number of males with high CVR according to D'Agostino,
a group in which clinical trials have shown a greater effi-
Distribution (in percentages) of the population in risk categories, overall and by sex, in the D'AGOSTINO and SCORE func- tions Figure 1
Distribution (in percentages) of the population in risk categories, overall and by sex, in the D'AGOSTINO and 
SCORE functions.
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Table 2: Classification of cardiovascular risk in the high and non-
high categories. Agreement in the high and low risk categories.
Assessment by SCORE Assessment by D'Agostino
Non-high CVR High CVR
Non-high CVR 311 (65.60%) 80 (16.88%)
High CVR 8 (1.69%) 75 (15.82%)
CVR: cardiovascular risk. Data are shown as n (%) of the total 
population analysed. Kappa: 0.52 (95% CI, 0.48–0.56); McNemar's test 
χ2 = 152.01. p < 0.001; discrepancies 18.57%.BMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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cacy of lipid lowering treatment for prevention of ischae-
mic heart disease.
The proportion of patients rated as having a high CVR
using the SCORE equation was higher than reported in
other studies seen in primary care [18,20] and in the gen-
eral population[12,21], and similar to the proportions
reported by studies on patients with hypertension or
hyperlipidaemia[19,27]. In this study, as in other studies
in similar populations[19,21,27], most female patients
were considered to have a low CVR using the SCORE
equation. By contrast, most patients analysed, both males
and females, were considered to have a moderate CVR risk
when the D'Agostino scale was used. Almost twice as
much patients are classified as having a high CVR with the
D'Agostino as compared to the SCORE equation, and
both scales assign a high CVR to a much greater propor-
tion of males, 4 males per each female.
These data suggest that the scale derived from the D'Ago-
stino equation overestimates CVR as compared to SCORE,
despite the fact that it calculates CVR instead of only cor-
onary risk, as occurred to date with the different versions
derived from the Framingham equation. This scale would
therefore have to be calibrated in our population, or a
higher cut-off point would have to be established to clas-
sify the same percentage of patients as having a high CVR.
Such cut-off point would be from 25% to 30%, the range
where the greatest agreement is found between both
scales.
The comparison reported in our study between the
SCORE and D'Agostino scales at the cut-off point of high
Proportions of subjects classified as high risk with SCORE (5%) and D'AGOSTINO at different cut-off points and agreement  with SCORE Figure 2
Proportions of subjects classified as high risk with SCORE (5%) and D'AGOSTINO at different cut-off points 
and agreement with SCORE. κ: Kappa index.
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k = 0.38±0,035
k = 0.52±0,042
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k = 0.65±0.048
k = 0.57±0.054BMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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CVR of 20% in hypertensive patients aged 40–65 years
with no cardiovascular history has not previously been
performed. This is the first analysis to compare two mor-
tality and morbidity and mortality scales measuring CVR.
This is probably the reason why agreement between both
scales shows a kappa index of 0.52, markedly better than
reported by other authors comparing the Framingham-
REGICOR and SCORE [19,21,27]or the Framingham and
SCORE scales[12,13,27,28]. The reasons for the poorer
agreement observed in previous studies may probably be
that while the Framingham function estimates coronary
morbidity and mortality, the SCORE equation estimates
cardiovascular mortality.
Among patients classified as high CVR, approximately 9
out of every 10 subjects in whom discrepancies were
found had high CVR according to the D'Agostino equa-
tion and non-high CVR according to SCORE, and only 1
had non-high CVR and high CVR using the D'Agostino
and SCORE equations respectively. These figures, while
substantial, are lower than the discrepancies reported in
other studies[12,20].
The profiles of discordant patients classified as having a
high CVR were different. Patients with high CVR in
SCORE and non-high CVR according to D'Agostino, the
least common profile, were older and had diabetes and a
lower atherogenic index. By contrast, patients with high
CVR according to D'Agostino and a non-high CVR using
SCORE were males with a higher atherogenic index. Dif-
ferent profiles have been reported by other
authors[12,13,20,21], all of whom agreed that the Fram-
ingham equation assigns a high CVR to a greater number
of males.
ROC curve for the D'Agostino scale versus SCORE 5% Figure 3
ROC curve for the D'Agostino scale versus SCORE 5%. The test result variable(s): Predicted probability has at least one 
tie between the positive actual state group and the negative actual state group.
Area Under the Curve         Test Result Variable(s): Predicted probability 
Area Std. Error
Asymptotic 
Sig.
Asymptotic 95% Confidence Interval
Upper Bound Lower Bound
,915 ,010 ,000 ,895 ,935BMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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From the data obtained, it can be concluded that males
with an unfavourable lipid profile and non-high CVR in
the SCORE scale probably show a CVR higher than esti-
mated with this scale, which should be considered by cli-
nicians when making therapeutic decisions.
Finally, use of the D'Agostino equation would imply treat-
ing more patients (particularly males) with lipid lowering
drugs. This agrees with the conclusion drawn by Maiques
et al [13] that SCORE promotes treatment in hypertensive
females and Framingham in dyslipidaemic males.
Study limitations include the fact that the patient sample
studied was not randomly taken from the general popula-
tion, but consisted of consecutive patients with clinical
hypertension referred to the research unit for ABPM for
different reasons, mainly to confirm diagnosis, but part of
the patients were already on antihypertensive and lipid
lowering treatment, which may alter estimation of their
cardiovascular risk. However, such limitations do not
invalidate the comparison of both equations, because
since all patients were assessed by both methods at the
same time, the design used was adequate for assessing
scale agreement without interfering with the comparison.
The primary objective was to estimate and compare the
CVRs inferred from both scales, as well as the prognostic
and therapeutic implications depending on the result
obtained. The scales are only an approach to the actual
risk for the subject and this paper intends to contrast both
risk estimation tools, though we are aware of the limita-
tions of the instruments, as evidenced in the paper. We
have been used as reference SCORE, recommend by Span-
ish and European regulatory authorities, because there
aren't gold standard scale, to compare the new D'Agostino
scale.
We have excluded from the analysis a very important pop-
ulation group where the prevalence of hypertension is
very high. The reasons for selecting this population group
is that the SCORE scale has been developed for a popula-
tion aged 40 to 65 years, and though the D'Agostino scale
allows for using it in a larger population group, the results
of the SCORE in the elderly could limit the validity of the
analyses performed.
Table 3: Characteristics of patients with discordant results using the SCORE and D'Agostino equations.
SCORE high-D'AGOSTINO non-high (n = 8) SCORE non-high-D'AGOSTINO high (n = 80) p
Males 4 (50%) 64 (80%) 0.054
Age (years) 62.69 ± 8.83 56.41 ± 5.6 0.003
Obese (BMI > 30) 3 (37.5%) 27 (33.8%) 0.831
Smokers 1 (12.5%) 29 (36.3%) 0.177
Diabetics 5 (62.5%) 17 (21.3%) 0.010
Hyperlipidaemic 2 (25%) 55 (68.8%) 0.014
BMI 31.6 ± 7.53 28.70 ± 4.40 0.102
Waist circumference 97.5 ± 9.77 99 ± 10.39 0.697
Glucose (mg/dL) 110.50 ± 40.59 105.82 ± 31.09 0.694
Cholesterol/HDL ratio 3.06 ± 0.81 4.76 ± 1.08 0.000
Total cholesterol (mg/dL) 196.50 ± 43.39 219.79 ± 36.39 0.093
HDL-C (mg/dL) 68.25 ± 25.10 47.64 ± 10.36 0.000
LDL-C (mg/dL) 107.13 ± 27.46 140.78 ± 34.01 0.008
Triglycerides (mg/dL) 105 ± 55.10 155.55 ± 96.74 0.151
Systolic blood pressure (mmHg) 137.75 ± 18.27 146.43 ± 17.87 0.195
Diastolic blood pressure (mmHg) 83.63 ± 9.33 91.11 ± 10.97 0.066
Antihypertensive drugs 3 (37.5%) 62 (77.5%) 0.014
Lipid lowering drugs 2 (25%) 20 (25%) 1
BMI: body mass index; Hyperlipidaemic: cholesterol > 200 mg/dl, HDL: high-density lipoprotein; HDL-C: high density lipoprotein cholesterol; LDL-
C: low density lipoprotein cholesterol. P value of the association of the typical differences and the probability of being a discordant patient (SCORE 
non-high-D'AGOSTINO high; SCORE high-D'AGOSTINO non-high). Data are shown as mean ± standard deviation or as number and percentages.
Table 4: Variables associated to discrepancies in classification as 
high CVR
Odds Ratio (95% CI) p
Age 1.089 (1.048–1.132) 0.000
Sex (1 = Male/0 = Female) 2.465 (0.384–4.390) 0.002
Smoker (1 = yes/0 = no) 1.858 (1.052–3.282) 0.033
Atherogenic index 1.475 (1.174–1.853) 0.001
M: Male; F: Female.
Dependent variable: 1 = (Discrepancy in classification between both 
scales); 0 = (Agreement in classification between both scales). 
Multivariate analysis (logistic regression). Atherogenic index = Total 
Cholesterol/HDL-Cholesterol. Significant model (χ2 = 54.285; p = 
0.000).BMC Cardiovascular Disorders 2009, 9:17 http://www.biomedcentral.com/1471-2261/9/17
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Conclusion
Discrepancies exist between the SCORE scale for low CVR
countries and the D'Agostino equation with regard to
both CVR assessment and identification of high CVR.
Agreement improves when a cut-off point for high CVR of
29% instead of 20% is used in D'Agostino scale. The find-
ing of discordant patient profiles may allow for a better
approach to the clinical assessment of CVR and for identi-
fication of patients who, while having a non-high CVR
according to SCORE, may have an actual CVR higher than
estimated. Patients in this group would be candidates to
lipid lowering treatment.
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